Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System
Gastaldon, C., Raschi, E., Kane, J. M., Barbui, C., & Schoretsanitis, G. | Psychotherapy and psychosomatics | December 2020
The psychoactive aminoalkylbenzofuran derivatives, 5-APB and 6-APB, mimic the effects of 3,4-methylenedioxyamphetamine (MDA) on monoamine transmission in male rats
Brandt, S. D., Walters, H. M., Partilla, J. S., Blough, B. E., Kavanagh, P. V., & Baumann, M. H. | Psychopharmacology | 01 September 2020
Plasma psilocin critically determines behavioral and neurobiological effects of psilocybin
Madsen, M. K., & Knudsen, G. M. | Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology | 25 August 2020
Ibogaine therapy for addiction: Consumer views from online fora
Barber, M., Gardner, J., Savic, M., & Carter, A. | Journal of Drug Policy | 18 July 2020
Perceived harm, motivations for use and subjective experiences of recreational psychedelic ‘magic’ mushroom use
Roberts, C. A., Osborne-Miller, I., Cole, J., Gage, S. H., & Christiansen, P. | Journal of Psychopharmacology| 17 July 2020
In vitro structure-activity relationship determination of 30 psychedelic new psychoactive substances by means of β-arrestin 2 recruitment to the serotonin 2A receptor
Pottie, E., Cannaert, A., & Stove, C. P | Archives of Toxicology | 5 July 2020
Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I)
Fu, D. J., Ionescu, D. F., Li, X., Lane, R., Lim, P., Sanacora, G., ... & Canuso, C. M. | 12 May 2020 | The Journal of clinical psychiatry
Chronic pain and psychedelics: a review and proposed mechanism of action
Castellanos, J. P., Woolley, C., Bruno, K. A., Zeidan, F., Halberstadt, A., & Furnish, T. | Regional Anesthesia & Pain Medicine | 4 May 2020
Exposure-Response Analysis to Assess the Concentration-QTc Relationship of Psilocybin/Psilocin
Dahmane, E., Hutson, P. R., & Gobburu, J. V. | Clinical Pharmacology in Drug Development | 06 April 2020
Long-term effects of psychedelic drugs: A systematic review
Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K., Davoli, C. C., & Davis, A. K. | Neuroscience & Biobehavioral Reviews | 15 March 2020
The Psychedelic Renaissance and Its Forensic Implications
Holoyda, B. | The journal of the American Academy of Psychiatry and the Law | 09 Mar 2020
Benefit-Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment-Resistant Depression
McIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. W., Berk, M., ... & Stahl, S. | American Journal of Psychiatry | 1 February 2020
A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses
Chi, T., & Gold, J. A. | Journal of the Neurological Sciences | 30 January 2020
Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials.
Fuentes, J. J., Fonseca, F., Elices, M., Farre, M., & Torrens, M. | Frontiers in Psychiatry | 21 January 2020
In vivo effects of 3,4-methylenedioxymethamphetamine (MDMA) and its deuterated form in rodents: Drug discrimination and thermoregulation.
Berquist, M. D., Leth-Petersen, S., Kristensen, J. L., & Fantegrossi, W. E. | Drug and Alcohol Dependence | 13 January 2020
Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species
Halberstadt, A. L., Chatha, M., Klein, A. K., Wallach, J., & Brandt, S. D. | Neuropharmacology | 7 January 2020
Lysergic acid diethylamide as an analgesic agent in patients with terminal illnesses
Das, S., & Maiti, T. | PAIN MANAGEMENT | 19 December 2019
Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers.
Family, N., Maillet, E. L., Williams, L. T., Krediet, E., Carhart-Harris, R. L., Williams, T. M., ... & Raz, S. | Psychopharmacology | 18 December 2019
Neurotrophic mechanisms of psychedelic therapy
Corne, R., & Mongeau, R. | Biologie aujourd'hui | 12 December 2019
Neurochemical and Behavioral Profiling in Male and Female Rats of the Psychedelic Agent 25I-NBOMe
Miliano, C., Marti, M., Pintori, N., Castelli, M. P., Tirri, M., Arfè, R., & De Luca, M. A. | Frontiers in Pharmacology | 12 December 2019
Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects.
Holze, F., Vizeli, P., Müller, F., Ley, L., Duerig, R., Varghese, N., ... & Liechti, M. E. | Neuropsychopharmacology | 16 November 2019
Locomotor effects of 3,4-methylenedioxymethamphetamine (MDMA) and its deuterated form in mice: psychostimulant effects, stereotypy, and sensitization
Berquist, M. D., Leth-Petersen, S., Kristensen, J. L., & Fantegrossi, W. E. | Psychopharmacology | 15 Nov 2019
Classical psychedelics for the treatment of depression and anxiety: A systematic review.
Muttoni, S., Ardissino, M., & John, C. | Journal of affective disorders | 30 July 2019
Metabolism of lysergic acid diethylamide (LSD): an update.
Libânio Osório Marta, R. F. | Drug metabolism reviews | 16 July 2019
First study of safety and tolerability of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in patients with alcohol use disorder: preliminary data on the first four participants
Sessa, B., Sakal, C., O’Brien, S., & Nutt, D. | BMJ Case Reports CP | 15 July 2019